Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.64 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.64 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.64 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.64 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.62 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.62 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.62 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.62 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.62 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.62 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.62 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.62 |
| ▸ | CCR3 | P51677 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6008856 | 0.99 | CARM1 (0.62) | CARM1PRMT6PRMT3PRMT1PRMT8 | |
| SCHEMBL6215029 | 0.84 | GRIN2B (0.85) | CARM1PRMT6PRMT3PRMT1PRMT8 | |
| SCHEMBL18233563 | 0.81 | CCR3 (0.67) | CARM1PRMT6PRMT3PRMT1PRMT8 | |
| SCHEMBL6008830 | 0.80 | PRMT6 (0.63) | CARM1PRMT6PRMT3PRMT1PRMT8 | |
| SCHEMBL6007462 | 0.80 | GRIN2D (0.58) | CARM1PRMT6PRMT3PRMT1PRMT8 | |
| SCHEMBL8814813 | 0.79 | GRIN2D (0.69) | CARM1PRMT6PRMT3PRMT1PRMT8 | |
| SCHEMBL543919 | 0.79 | PRMT6 (1.00) | CARM1PRMT6PRMT3PRMT1PRMT8 | |
| Hydrochloric Acid SCHEMBL7253251 | 0.78 | GRIN2D (0.67) | CARM1PRMT6PRMT3PRMT1PRMT8 | |
| SCHEMBL28316666 | 0.78 | ALDH1A1 (0.54) | MEN1KMT2ASIGMAR1SLC6A3 | |
| SCHEMBL9796769 | 0.78 | ALDH1A1 (0.54) | MEN1KMT2ASIGMAR1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078537-B2 | Phenylalkyl diamine and amide analogs | SK CORPORATION (KR) | 2006-07-18 | — | — | US | disclosed |
| EP-1401821-A4 | NOVEL PHENYLALKYL DIAMINE AND AMIDE ANALOGS | SK CORP (KR) | 2006-05-31 | — | — | EP | disclosed |
| US-20050192291-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2005-09-01 | — | — | US | disclosed |
| EP-1158980-B1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6919368-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-6906066-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-6897234-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-05-24 | — | — | US | disclosed |
| US-20050096325-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2005-05-05 | — | — | US | disclosed |
| US-6875776-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-6780857-B2 | FOR TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES SUCH AS ASTHMA AND ALLERGIC DISEASES, AS WELL AS AUTOIMMUNE PATHOLOGIES SUCH AS RHEUMATOID ARTHRITIS AND ATHEROSCLEROSIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-24 | — | — | US | disclosed |
| EP-1158980-A4 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARM CO (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1140087-A4 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARM CO (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001098270-A2 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| US-6331541-B1 | TREATING ASTHMA, ALLERGIC RHINITIS, ATOPIC DERMATITIS AND INFLAMMATORY BOWEL DISEASES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-12-18 | — | — | US | disclosed |
| EP-1158980-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-12-05 | — | — | EP | disclosed |
| EP-1140086-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140087-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035451-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000035453-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000035454-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096325-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | CARM1 1013/4885PRMT6 868/4885PRMT3 201/4885 |
| US-20050192291-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | CARM1 1013/4885PRMT6 868/4885PRMT3 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.